Bio Screening Industry News

Archive for the 'Compound Libraries' Category

January 11, 2010

Developments in Focused Kinase Libraries

Filed under: Press Releases, Compound Libraries, Compound Screening — Editor @ 3:14 pm

Chemical libraries have long been a mainstay in the search for new pharmaceutical compounds, and they have been created using many different paradigms. Vast diverse collections of unique compounds have been screened at high throughput to find appropriate effects on target proteins. Such large libraries continue to be used for drug discovery, but screening smaller, more focused libraries, can provide more efficient solutions with better overall hit rates.

Ten years ago, BioFocus®, a Galapagos company, launched a nonexclusive compound library specifically designed to target serine-threonine and tyrosine kinases. This library, SoftFocus® Kinase library one (SFK01), was designed to mimic the binding of ATP to the catalytic (hinge) region and had a rather simplistic design based around an aminopyrimidine core (Figure 1).

Targeting Kinases
Protein kinases are enzymes that phosphorylate substrate proteins at specified residues such as serine, threonine, and tyrosine. The phosphorylation of the substrate protein initiates a cascade, that in turn, modulates the transcription of a gene or set of genes. Kinases play pivotal roles in modulating diverse cellular activities, including growth, differentiation, metabolism, adhesion, motility, and death, and have been implicated as important mediators of certain forms of cancer.

Kinases, therefore, represent key druggable target proteins. The initial realization that most kinases possess highly conserved catalytic domains initially made kinase targets ideally suited for compound screening via focused chemical libraries in which the library compounds were specifically created to bind to the catalytic (hinge) regions.

Despite the slightly higher costs generally associated with the design and synthesis of such focused libraries compared to large and diverse compound collections, true savings can be gained as a result of shortened project cycles coupled with the reduced costs of screening, storage, and quality control of a smaller screening library.

The increasing wealth of structural data available along with a number of new techniques such as in silico design has enabled the continual development of kinase-focused collections, providing increasingly more sophisticated chemical structures. One of the key benefits of this is that the current range of SoftFocus kinase libraries has been designed to target additional binding modes to those involving the hinge region; most notably the DFG-out binding mode and the novel binding mode first observed in the kinase PIM-1.

In Silico Design

Current in silico design processes enable automated docking and scoring of scaffold ideas into a variety of known x-ray structures that have been selected, not only for broad coverage of the kinome, but also different conformational states of individual kinase enzymes. The design premise is that, if the core of the molecule or scaffold contains the key recognition groups for binding into one of the known conformational states, it has the potential to target any kinase.

However, as different side chains or monomers are added, the potential to gain specificity for one target over another becomes reality. The various docking methods used in the design of the BioFocus libraries include hinge binding, the DFG-out model, and novel binding modes.

Hinge Binding
Hinge-binding library designs are validated by docking a minimally substituted scaffold into various different high-resolution kinase x-ray structures. These structures have been selected from across the phylogenetic tree to ensure broad coverage of tyrosine and serine/threonine kinases.

The BioFocus Kinase Toolkit™ provides a two-dimensional map (2D Roadmap) of the key ligand-binding features within a customized ATP-site model, allowing predictions of affinity, selectivity, and likely off-target issues based on the compositions of the individual sub-sites. This knowledge can then be used to select the appropriate side chains or monomers with which to decorate the scaffolds.

DFG-Out Model

An approach to the design of kinase libraries with higher selectivity potential is to target the DFG-out allosteric pocket adjacent to the ATP site. BioFocus has developed a generalized binding model of the DFG-out pocket that enables the targeting of a range of inactive kinase conformations.

Binding Modes

click to enlarge

Figure 2. Ribbon diagram showing the binding of a potent SFK33 compound to the kinase PIM-1
A library design strategy focusing on alternative ligand-kinase binding modes is largely based on the novel binding modes observed in the cocrystal structure of a potent compound from a SoftFocus library (SFK33), bound to the kinase PIM-1 (Figure 2). In this case, the compound binds to a catalytic lysine residue while  making no contact with the hinge region. This binding mode provides a unique paradigm for novel library design.

Only those scaffold ideas that pass this in silico docking are progressed to the next stage of evaluation, which includes a novelty check on structures and adherence to key hit/lead physicochemical property checks. Screening such libraries has generated information-rich data, generally consisting of higher hit rates (compared to screening diverse collections of unrelated compounds) together with key structure-activity relationship data that can speed up hit-to-lead programs.

Focusing on Success

By constantly refining the compounds using in silico methods, including those described above and with the development of innovative in silico models and applications such as Cresset BioMolecular’s molecular Field technology, the latest advances in kinase research can be incorporated into novel libraries. Consequently, this may also provide a strong intellectual property position to those who screen them. Indeed, based on the screening of SoftFocus kinase libraries alone, over 70 known patents have been applied for or granted.

A recent example from Galapagos highlights this. Following a screen of some 16,000 BioFocus focused kinase compounds, three hit series were identified that showed structure-activity relationships against a novel rheumatoid arthritis target. Two of these compound series were progressed to the hit-to-lead phase and subsequently one series was optimized, and a compound is currently undergoing clinical trials. The project time from screening to preclinical candidate nomination was three years.

There is no doubt that the drug discovery process should be shortened whenever possible. It is essential to improve the lead discovery process. Focused compound libraries such as the SoftFocus collection have the inherent capabilities to provide a robust hit discovery process, with good hit-to-lead conversion rates and shorter development times.

Furthermore, such libraries can maximize the benefit of new techniques such as in silico modeling, enabling them to be consistently developed over time. BioFocus has also maintained flexibility in its library-generation processes using these techniques, which has enabled the development of novel libraries with proven results.

Source: genengnews.com

December 15, 2009

Computational Method Points To New Uses, Unexpected Side Effects Of Already Existing Drugs

Scientists at the University of North Carolina at Chapel Hill School of Medicine and the University of California, San Francisco have developed and experimentally tested a technique to predict new target diseases for existing drugs.

The researchers developed a computational method that compares how similar the structures of all known drugs are to the naturally occurring binding partners — known as ligands — of disease targets within the cell. In a study published this week in Nature, the scientists showed that the method predicts potential new uses as well as unexpected side effects of approved drugs.”This approach uncovered interactions between drugs and targets that we never could have predicted simply by looking at the chemical structures,” said senior study author Bryan Roth, M.D., Ph.D., professor of pharmacology and director of the National Institute of Mental Health Psychoactive Drug Screening Program at UNC. “We may now have a way to predict what side effects are likely to occur from treatment before we even put a drug into clinical testing.” Roth is also a member of the UNC Lineberger Comprehensive Cancer Center.

Many of the most successful drugs on the market today are being prescribed for ailments that are quite different from the ones they were originally designed to treat. Viagra, for instance, was once intended for coronary heart disease but now is used to combat erectile dysfunction. The discovery of surprising uses of developed drugs can sometimes be the result of serendipity, as unforeseen side effects emerge from clinical trials. In the past, researchers have tried to predict drug interactions by looking for chemical similarities among the possible targets of pharmaceutical compounds.

However, some drug targets which look very similar to one another bind very different ligands, and some targets that don’t have any obvious similarity bind similar ligands, says Brian Shoichet, Ph.D., co-senior study author and professor of pharmaceutical chemistry at the University of California at San Francisco. “So if instead we were to organize targets by the ligands they recognize, it could reveal different patterns than traditional approaches, and illuminate new opportunities for drugs to bind to unexpected targets.”

A team of researchers led by Roth and Shoichet did just that, comparing the structures of 3,365 FDA-approved and investigational drugs against the structures of hundreds of targets, defining each target by its ligands. They then honed in on thirty of the strongest predictions, validating the actual physical interactions between the drugs and targets in wet laboratory experiments.

In one of their follow-up experiments, the scientists investigated the molecular targets of the hallucinogenic substance dimethyltrytamine (DMT), which had previously been postulated to act through a site known as the sigma-1 receptor. Using the computational approach, Roth and colleagues found that DMT had a high affinity for serotonin receptors, including the binding site for LSD, another hallucinogen.

They also showed that the substance is hallucinogenic in normal mouse models but not in ones lacking the serotonin receptor. Roth says the power of their approach is it can be used to uncover the real targets of pharmaceutical compounds quickly and efficiently, and will probably lead to a greater understanding of the many molecular targets of each drug.

“Drugs are not as selective as we once thought,” said Roth, who is also a professor in the School of Pharmacy’s medicinal chemistry and natural products division. “It turns out that the most non-selective drugs are frequently the most effective for complex diseases. Rather than ‘magic bullets,’ we need to come up with ‘magic shotguns’ that hit more than one molecular target at a time. We could use this computational approach to identify the drugs that hit the right targets and miss the wrong ones.”

Study co-authors from UNC include Vincent Setola, research associate professor; Atheir Abbas, former graduate student; Sandra J. Hufeisen, senior research assistant; Niels H. Jensen, research associate; Michael B. Kuijer, research technician; Roberto C. Matos, research technician; Thuy B. Tran, research technician; Ryan Whaley, research technician; and Richard A. Glennon. The paper’s first author is Dr. Michael Keiser, from the UCSF side of the collaboration. Also from UCSF were Drs. John Irwin, Christian Laggner and Jerome Hert, and PharmDs Kelan Thomas and Douglas Edwards.

Funding for the studies at UNC and at UCSF came from the National Institutes of Health.

ScienceDaily (Nov. 7, 2009)

October 12, 2009

Trophos launches the new generation of its fast plate imaging instrument, the Plate RUNNER HD

Marseille, FRANCE, 2009 September 29 - Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology, announced today the launch of the new generation of its fluorescence fast plate imaging system, the Plate RUNNER HD(R).

Trophos originally developed the Plate RUNNER HD(R) to speed up its own screening campaigns for drug discovery and development. The company has now implemented an improved version which offers much better resolution and allows imaging of the 7mm well of the standard 96 plate in matrices of up to 8192 x 8192 pixels. This positions it as the superior alternative to the traditional automated microscope in a wider area of cellular and small organism imaging applications such as neurite outgrowth or C.elegans screens. The Plate RUNNER HD(R) is protected by patents granted in the USA and Europe.

“The Plate RUNNER HD(R) has now reached both a performance and an operational level that allows it to be widely used in various imaging platforms,” said Damian Marron, CEO of Trophos. “We have optimized it by regular use in our screening and research platforms. Use in other labs such as the Neuronal Cell Biology & Pathology research unit directed by Dr Christian Neri at the Inserm Psychiatry and Neurosciences Centre (Paris, France) and the Laboratory of Motor Neuron Biology directed by Dr Alvaro G. Estévez at the Burke Medical Research Institute (NY, USA) has confirmed its performance.” (For further information, see http://www.broca.inserm.fr and http://www.burke.org).

The Plate RUNNER HD(R) fills the gaps between the low sensitivity/low resolution/cell consuming fluorescence plate readers, the high sensitivity but non-imaging flow cytometer, and the slow, poorly automated and small field fluorescence microscope. It does this by allowing whole well/full plate imaging in just 2 minutes 40 seconds for 96 images of 1024 x 1024 pixels, 8 minutes at 4096 x 4096 resolution and 25 minutes at the extremely powerful 8192 x 8192 resolution. The maximum resolution gives details as fine as 1 micron, which covers the vast majority of cellular imaging applications.

“The instrument is not only the source of our pipeline - nearly 1 million compounds screened in eight years - but also an everyday research tool that does in two minutes a job that usually requires a week manually,” said Pierre Delaage, Head of Development of Trophos Instruments. “Using exclusively open data formats, the Plate RUNNER HD(R) integrates smartly and smoothly with all existing imaging and data processing environments with no hidden extra costs. It is also a “green product” using at least ten times less electrical power for illumination than its competitors. It has the important advantage of having a lower price and TCO than the traditional microscope-based instruments.”

Dr Christian Neri, Research Director at the Psychiatry and Neuroscience Center of Inserm in Paris, stated “We have been using the Trophos screening system since its first commercial version; it allowed us to simply and rapidly automate our screening protocols on C.elegans worms and on cells. To move further in C.elegans screens we needed a far higher resolution without sacrificing light, sensitivity and field. We have now seen that Trophos’ latest instrument meets perfectly our very stringent requirements.”

“We continue to directly sell and support the Plate RUNNER HD(R) and are now looking to set up a commercial and industrial partnership to address more widely the global market opportunity,” added Marron. “The Plate RUNNER HD(R) offers unique performance and can be a great fit for imaging solutions manufacturers and vendors, to exploit opportunities for example in the area of small organism or angiogenesis screens as well as cellular screens.”

About the Plate RUNNER HD(R): Developed by Trophos since 1999 initially for its own HTS platform, The Plate RUNNER HD(R) is a rapid fluorescence 96-plate imager giving full 7mm well images in single snapshots (ie no mosaic reconstruction), embedding three commonly used wavelength illumination lamps using fast-switching LED technology, thus leading to more homogeneous light, very long life time (100 000 hours against 5000 hours for xenon or mercury lamps), higher speed and dramatically reduced maintenance costs. Images are given in standard 1024 x 1024 definition but also in higher 2048 x 2048, 4096 x 4096 and even 8192 x 8192 pixels definition, leading to details of about 1 micron in size.

Compared to classic automated microscopes, The Plate RUNNER HD(R) is much more simple, integrated, automated, robust and fast; it has no oculars (eyepieces), no huge frame, no complicated auto focus system, no complicated settings, no complicated software, and does not need any cooling/heating delay between illumination sessions nor painful recalibration between sessions. Built on modular, open and interoperable design and data formats, it is compatible with any existing image processing platform. Training for common tasks is achieved in less than 1 hour, and there is no need of high skilled people to install or set it up.

Driven by Trophos proprietary software running on standard low cost PCs and using advanced real time programming techniques coming from the industry, the device reliably acquires 96 images at 1024 x 1024 definition in just 2 minutes 40 seconds (for a standard 488nm excitation and 200ms exposure time), 8mn for 4096 x 4096 images and 25mn for 8192 x 8192 images.

The device is patent protected in France, Europe and USA. Patent is pending in Canada and Japan. Detailed specifications are available here (http://www.trophos.com/download/pr_datasheet.pdf).

About Trophos: http://www.trophos.com Trophos is a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology. The Company has a novel and proprietary cholesterol-oxime based chemistry platform generating a pipeline of drug candidates, with the lead product, olesoxime (TRO19622), in phase II clinical trials and a second product, TRO40303, planned to enter the clinic in 2010. Trophos’ mitochondrial pore modulator compounds enhance the function and survival of stressed cells via modulation of dysfunctional mitochondria through interactions at the permeability transition pore (mPTP). Recently published clinical studies support the therapeutic rationale for mitochondria targeted drugs in neurology (Alzheimer’s disease) and cardiology (ischemia-reperfusion injury), which Trophos is uniquely placed to exploit.

Trophos has not only invested in science but also in technology such as the Plate RUNNER HD(R), which is a key reason why Trophos was able to bring products into phase II clinical trial after only 8 years, instead of the 12-15 or even 20 years commonly observed”.

For further information, please contact:

Andrew Lloyd & Associates Andrew Lloyd / Neil Hunter Tel: +44 1273 675100 allo@ala.com

Source: medadnews.com

October 10, 2009

Zelinsky Institute Inc. announced collaboration with ART-CHEM

Zelinsky Institute Inc. (Newark, DE, August 2009) - Zelinsky Institute Inc. expands its partnership and supplier network with the announcement of collaboration with one of the premier fine chemistry companies - ART-CHEM, which originated from Moscow, Russia, and has started its operations in Berlin, Germany, in 2005. ART-CHEM specializes in synthesis of highly diverse and rich in unique scaffolds HTS compounds and building blocks. The entire line of ART-CHEM product offerings is going to be available via Zelinsky Institute Inc., which is headquartered in and currently operates from Delaware, USA, offices.

ART-CHEM founder, Dr. B. Ugrak, comments, “We are pleased to become a part of Zelinsky Institute, a recognized supplier of specialty chemicals. Together we can provide greater value serving our, now, joined customer base.” Zelinsky Institute CEO, Dr. M. Niazoff, agrees adding, “We are happy to have ART-CHEM high quality fine chemistry products and service capabilities accessible via Zelinsky Institute. Together, we are looking forward to growing our market fueled by ever-evolving research demands.”

Collaboration aims at making ART-CHEM products and services known and easily accessible for existing and prospective Zelinsky Institute Inc. customers worldwide. September 2009 product databases distributed by Zelinsky Institute Inc. are going to include ART-CHEM’s drug-like and chemically diverse compounds for screening, building blocks, and intermediates. Zelinsky Institute Inc. is going to coordinate procurement, orders, and consolidated delivery of HTS products. Zelinsky Institute Inc. and ART-CHEM collaboration is open to custom projects going beyond the supply of just existing fine organic chemistry. For recently launched databases, products and services, inquiries, orders, and customized solutions please contact

October 9, 2009

Sirona Biochem Says SGLT Test Results Confirm Key ‘Breakthrough’

Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on diabetes and obesity, says results of testing its unique SGLT inhibitor molecules demonstrate a key breakthrough milestone for Sirona Biochem.

Sirona Biochem CEO, Dr. Howard Verrico, said, “There are two vital steps in the early stage of drug testing: validation of concept i.e. a molecule is able to hit the desired target and secondly its in vivo effectiveness. This first round of testing has shown a key breakthrough milestone in the process of validating this concept.”

“The test results now mean we can proceed to find out whether the molecules are selective, safe and robust enough to have potential to be effective when they reach the parts of the body where the re-uptake of glucose needs to be limited.”

Dr. Bertrand Plouvier, Chief Scientist, said, “The results from the first round of screening are indeed very encouraging and Sirona Biochem will use the next following months to further study the molecules through specific assays to demonstrate their effectiveness and drug likeness.”

Dr. Verrico said management of sugar metabolism is a primary medical challenge associated with treating diabetes and obesity and that is why SGLT inhibitors show such promise in this regard. “At present SGLT2 inhibitors have demonstrated their ability to limit the re-uptake of glucose back into the blood stream from urine. However, they have been notoriously lacking in ability to resist being rapidly metabolized by the body, thus rendering them largely ineffective.

“What we have now done is show that our molecules, with their unique GlycoMim® technology, can inhibit the glucose transporter SGLT2. The next challenge, and an exciting one, is to show that our molecules are selective, safe and have the potential to have an increased efficacy compared to the current molecules undergoing clinical development.”

Sirona Biochem owns the worldwide product rights to a library of unique sodium glucose transporter (SGLT) inhibitors to treat diabetes and obesity. SGLT inhibitors, as previously stated, block the re-uptake of excess sugars from urine, which can then reduce high blood sugar towards normal levels.

Sirona Biochem has entered into a strategic partnership with TFChem, a drug discovery company based in Rouen, France. TFChem licenses its technology of fluorinated carbohydrate mimics: GlycoMim®, and products in development to biotech companies. This strategic partnership was completed by a detailed research and licence agreement signed on September 29, 2008.

23.6 million people, or 7.8% of the population of the United States, have diabetes. (February 2009 DACG.ORG)

Market Trends

In 2007, the prevention and treatment of diabetes and its complications was estimated to cost US$ 232 billion according to the International Diabetes Federation. By 2025, this is likely to increase to more than US$ 302.5 billion.

The diabetes drug market reached US$18 billion in 2005, and is expected to increase to $21-25 billion in 2011. With many new products yet to realise their full potential and the high incidence of T2DM expected in emerging markets, prospects for the sector look strong. Some of the fastest growing markets for diabetes are in emerging economies. India, China and Indonesia are in the top 5 for disease prevalence. The impact for both branded and generic drugs is considerable.

Furthermore, in recent years, obesity has become a major health problem for many post-industrial societies, so much so that in 2004, the United States Health and Human Services declared obesity to be a disease. The World Health Organization (WHO) projects that globally in 2005, 1.6 billion adults were overweight with at least 400 million adults obese. By 2015, approximately 2.3 billion adults will be overweight and 700 million will be obese. Obesity poses a major health risk because it greatly increases the risk of co-morbidities such as diabetes, cardiovascular diseases, arthritis, and cancer. Recognizing the potential for a new blockbuster market, major pharmaceutical companies have increasingly focused on obesity and its causes and, in the process, seeking to identify many potential targets and pathways that could be exploited to create novel therapies.

Sirona Biochem’s website is at: www.sironabiochem.com where we feature the most recent information about the company and its activities. Alternatively, investors are able to e-mail all questions and correspondence to info@sironabiochem.com where they can also request to be added to the investor e-mail list to receive all future press releases and updates or call John Dougherty, Corporate Development at 604-641-4466.

About Sirona Biochem

Sirona Biochem Corp. (TSX-V: SBM) is an emerging biotech company dedicated to the discovery and development of novel drug compounds. The current focus is on treatments for Type II diabetes and obesity. Sirona has entered into a license agreement with TFChem S.A.R.L., a drug discovery company based in Rouen, France. TFChem licenses its technology of fluorinated carbohydrate mimics: GlycoMim®, and products in development to biotech companies. The license agreement with TFChem provides for research and development of new compounds known as SGLT Inhibitors. SGLT inhibitors are a new and exciting class of compounds that have great promise and potential to treat both diabetes and obesity.

Mark Senner
President and Director

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem Corp.
950-789 west pender street
vancouver, b.c., v6c 1h2
Direct: 604-641-4466
Fax: 604-608-5471
info@sironabiochem.com

Source: Marketwire

October 8, 2009

Agilux Laboratories Hires New Associate Director to Lead In Vitro ADMET Services Division

- Adrian Sheldon, Ph.D., Positions Contract Research Organization for Growth -
WORCESTER, Mass.--(Business Wire)--
Agilux Laboratories, Inc., a Contract Research Organization (CRO) that provides
bioanalytical and in vitro Absorption Distribution Metabolism Excretion
Toxicology (ADMET) services for the biotechnology and pharmaceutical industries,
has appointed Dr. Adrian Sheldon as associate director of In Vitro ADMET
Services. In this role, Dr. Sheldon will build the In Vitro ADMET Services
division offering testing services that allow biotechnology and pharmaceutical
companies to screen drug candidates for desirable ADMET properties. Dr. Sheldon
will leverage more than 17 years of industry experience, including establishing
new business units for In Vitro ADMET and Immunochemistry within an established
CRO. He will extend Agilux`s emphasis on customer service, rapid turnaround and
exceptional data quality to the company`s newly formed In Vitro ADMET Services
Testing Division.

"We are excited to have someone with Adrian`s expertise, successful track record
and demonstrated abilities at Agilux," said Jim Jersey, president and CEO at
Agilux. "Adrian brings the right balance of scientific expertise and customer
focus, which is consistent with Agilux`s mission of delivering high quality data
at unprecedented speeds. We are confident that both the Agilux team and our
clients will benefit from his unique skill set."

Prior to Agilux, Dr. Sheldon served as associate director of In Vitro ADMET at
Charles River Laboratories. Prior to Charles River Laboratories, Dr. Sheldon was
group leader in Assay Development/HTS/In Vitro ADMET at ArQule where he
co-managed a team responsible for screening compounds generated by the
industry-leading combinatorial chemistry laboratory. He received his Ph.D. from
Boston University and his A.B. from Harvard University. Dr. Sheldon has authored
numerous scientific publications and holds two patents.

"I am very pleased about joining the team at Agilux," stated Dr. Sheldon. "We
have an incredible opportunity to change the way early stage development
services are delivered and I am confident that I will be able to contribute to
Agilux`s continuing success."

About Agilux Laboratories, Inc.

Agilux Laboratories, Inc. is a privately held contract research organization
(CRO) focused on bioanlaytical and PK/PD testing services for the biotech and
pharmaceutical industries. Leveraging industry and contract research experience
of its management team, the company delivers high quality bioanlaytical
chemistry and PK/PD data more rapidly. Agilux helps clients make better
decisions during drug discovery and development by providing quality data
earlier in the research process by using technologies and systems that increase
turnaround speed well beyond industry standards. Founded in 2007 by industry
experts Jim Jersey, Steve Guyan and Peter Glick, Agilux is headquartered in
Worcester, MA and is funded by private equity firm, Ampersand Ventures. For more
information, call 508-753-5000 or email sguyan@agiliuxlabs.com. Online at
www.agiluxlabs.com.

Agilux Laboratories, Inc.
Steve Guyan
Vice President, Sales and Marketing
508-762-4402
sguyan@agiluxlabs.com
Source: Reuters

September 9, 2009

Bayer CropScience invests EUR 4.9 million in compound logistics

Filed under: Press Releases, Compound Libraries, Compound Screening — Editor @ 10:31 am

7 Sep 2009 , Monheim : Bayer CropScience has invested EUR 4.9 million in the expansion of the compound logistics at its Monheim site. It has one of the most modern facilities in the world for storing chemical compounds. The company’s scientists use the 2.2 million or so substances currently in the collection to search for promising active ingredients for innovative crop protection products. After just 15 months of construction, the extension was inaugurated at a ceremony attended by Dr. Alexander Klausener, Head of Research at Bayer CropScience.

The purpose of the compound logistics is to store, prepare and distribute substances prior to comprehensive biological testing. “We are now in a position to pursue our research and development activities even more efficiently than before,” Dr. Klausener explained. With expenditures of EUR 649 million in research and development (2008), Bayer CropScience is one of the leading companies in its sector.

The central feature of the compound logistics, which has been extended to cover more than 1,000 square meters, is the substance storage area. The automatic miniload warehouse with some 24,000 storage positions now has space for about 7.6 million vials containing minute quantities of different chemical compounds. Placed side by side, the vials would cover a distance of around 161 kilometers. A total of 16 robots and retrieval units “work” in the facility, where they achieve a high throughput. They quickly supply researchers in Bayer CropScience’s institutes with the exact quantities they need; this spares resources and, above all, ensures “just in time” delivery. The investigational substances undergo a comprehensive screening procedure, in which they are tested to see whether they have a desired effect, for example in controlling fungal pathogens, insect pests or weeds, and could thus be suitable as the starting point for developing a new product.

About Bayer CropScience
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer CropScience AG, a subsidiary of Bayer AG with annual sales of about EUR 6.4 billion (2008), is one of the world’s leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and plant biotechnology. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of more than 18,000 and is represented in more than 120 countries. This and further news is available at: www.press.bayercropscience.com.

More information is available at www.bayercropscience.com

September 8, 2009

Baylor researchers find fat cell blocker

The guilt-free double Whopper experience is inching closer.

A small molecule that turns off the genes responsible for making fat cells has been discovered by a team of Baylor College of Medicine and Japanese researchers.

Dubbed “fatostatin,” the molecule blocks a protein in the cell that starts the cascade of events that turns on the 63 genes in the nucleus responsible for the generation of fat cells, said Salih Wakil, professor of biochemistry and molecular biology at BCM.

The report appears in the journal Chemistry and Biology.

“That is the exciting thing,” said Wakil. “This goes to the most basic level of the expression of genes that cause fat.”

When mice with a predisposition to be obese received fatostatin, they lost weight, their cholesterol and fatty acid synthesis decreased. They had less resistance of insulin (a factor in diabetes), and their livers, which were pale because of fat buildup, returned to normal.

Drugs that lower cholesterol already exist, but they block only a single enzyme in the fat-generating pathway. Fatostatin stops the process at the beginning, said Wakil.

Wakil said one of his colleagues, Motonari Uesugi, now of Kyoto University in Japan, discovered the compound by screening a library of an estimated 10,000 compounds.

Lutfi Abu-Elheiga, associate professor of biochemistry and molecular biology at BCM was also a major contributor.

Source: bizjournals.com

August 26, 2009

Researchers develop screening test for cells that activate immune system

UT Southwestern Medical Center researchers are the first to design a large-scale, cell-based screening method that identifies which compounds activate immune-return cells that hold compact for prospective cancer-fighting vaccines.
The new screening technique can scan thousands and even millions of compounds to identify those that activate dendritic cells, which are on constant recon patrol throughout the body to scout out cancerous or infected cells and alert the immune system.
“Our assay is unique from other conventional ones in its sensitivity and cost- and time-efficiency,” said Dr. Akira Takashima, professor of dermatology and vice chairman for research and head of the project.
Dendritic cells (DCs) are considered key to developing future vaccines that can either mimic the body’s natural immune response or turn on immune responses that failed - due, for example, to cancer or an immune deficiency.
The team, which also included Dr. Norikatsu Mitzumoto, assistant professor of dermatology and the study’s lead author, and Drs. Hironori Matsushima and Hiroaki Tanaka, postdoctoral researchers in dermatology, created the cell-based biosensor system.
“We basically engineered DCs to express a fluorescent signal only when sensing activation signals so that you can identify immuno-stimulatory agents very easily,” said Dr. Takashima. Immuno-stimulatory agents launch the immune system.

Buy exelon

The research appears on Blood magazine’s online Web site and will appear in a future issue.
“We have optimized the high-throughput screening capability - an experienced scientist can now test one thousand chemicals a day almost single-handedly,” added Dr. Mizumoto. Previously, scientists would have to test each compound individually, a time-consuming process.
Their research already has led to the discovery of several compounds that turn on dendritic cells, which are found throughout the body from skin to blood. They continuously scan the body at the cellular level looking for antigens - foreign cells and materials invading the body - and for molecular signatures of tissue damage or infection.
“Their primary job is to present antigens to the immune system so that you develop protective immunity for infection and cancer,” said Dr. Takashima.
The DC biosensor system should help pharmaceutical and biotech companies sift through large numbers of chemicals for ones that tell the dendritic cells to launch the immune response. It may also prove useful in identifying biothreat agents because it detects infectious pathogens with high sensitivity.
Dr. Takashima said he hopes to garner additional funding to discover potent immuno-stimulatory drugs by screening high-quality libraries of compounds.
Doing so may be the first step toward developing a new class of vaccines that force or trick the natural immune system to kick on, or initiate an immune response that can be copied and initiated artificially.
Other UT Southwestern researchers from dermatology involved in the study were Dr. Yasushi Ogawa, postdoctoral researcher, and Dr. Jimin Gao, former instructor.
The research was funded by the National Institutes of Health, the Dermatology Foundation Career Development Award and the American Cancer Society Junior Investigator Award.
http://www.utsouthwestern.edu/

May 13, 2009

TimTec Expands Partnership With Collaborative Drug Discovery Through Publishing Three Additional Libraries on CDD’s Free Public Access Database

Last October, TimTec and Collaborative Drug Discovery (CDD) established a collaboration in which CDD’s web-based data management system would host two TimTec Natural Products libraries on their free community Public Access site.  Through this partnership, researchers would be able to register for a free account with CDD allowing them to chemically mine the contents of these TimTec compound libraries using CDD’s powerful, intuitive web-based database software.

TimTec is now offering three more libraries on the CDD Public Access database:

The TimTec ActiTarg-K Kinase Modulators library contains over 6,000 compounds known to inhibit protein kinase activity:

http://www.timtec.net/actitarg-k-kinase-modulators.html

The TimTec OGT Inhibitors Analogs library contains more than 300 compounds analogous to three known O-GlcNAc Transferase inhibiting molecules:

http://www.timtec.net/o-glcnac-transferase-inhibitors.html

Finally, the TimTec resourceful Diversity Set is a general screening collection of drug-like compounds that present most diversified selection from TimTec stock. This screening library contains 10,000 of the most diverse compounds, all complying with the Lipinski Rule of Five:

http://www.timtec.net/diversity-set-10k.html

TimTec’s five databases join more than 25 other databases containing chemical and biological data hosted on CDD Public Access, including:

  • 47,000 Ki values for 20,000 compounds against 699 GPCR targets from the NIMH Psychoactive Drug Screening Program at the University of North Carolina
  • Over 15,000 compounds with Malaria assay data from 5 public data sources
  • 48,818 compounds from the Distributed Drug Discovery (D3) at Indiana University – Purdue University Indianapolis (IUPUI)
  • Almost 7,500 compounds with Tuberculosis antibacterial and cell viability information from 4 public data sets and growing thanks to their collaboration with the Bill & Melinda Gates Foundation

About TimTec, LLC.

TimTec LLC. - http://www.timtec.net - is a privately held company located in NewarkDelaware, USA. It was founded in 1995 and began its work in the areas of acquisition and distribution of synthetic organic and natural compounds, custom synthesis, and laboratory equipment to become a full service partner for drug discovery. TimTec has established a global network of thousands of scientists from research centers around the world. The company has developed strong in-house expertise assembling general and targeted library collections for variety of research purposes. International customers include major pharmaceutical, biotech, agricultural, and educational companies and institutions, which use TimTec products for research and development programs.

For more information on TimTec library collections, please contact:

Kay Denisova
Business Development
TimTec LLC
Harmony Business Park Building 301-A
Newark, DE 19711
Tel 302 292 8500
Fax 302 292 8520
info(at)timtec.net
http://www.timtec.net

About Collaborative Drug Discovery, Inc.

Collaborative Drug Discovery, Inc. (CDD) - http://www.collaborativedrug.com - provides web-based software that organizes preclinical research data to help scientists advance new drug candidates more effectively. The CDD database enables scientists to “archive, mine, and collaborate”® around preclinical chemical and biological drug discovery data through a web-based interface. The software helps distributed research groups to safely store and intelligently analyze small molecule, enzyme, cell and animal bioactivity data accumulated from both low-throughput and high-throughput screens. Unique collaboration features and CDD’s community-oriented approach help unite globally dispersed humanitarian efforts against neglected infectious diseases. Similar collaborative strategies are also rapidly gaining prominence in the commercial arena. CDD offers its industrial-strength database software at a price affordable to academic laboratories, research foundations, and small companies.

For further information please contact:

Barry Bunin, PhD
President & CEO
Collaborative Drug Discovery (CDD)
1633 Bayshore Hwy, Suite 342
Burlingame, CA 94010
info(at)collaborativedrug.com

Next Page »

Powered by WordPress